Tumour-informed ctDNA

Detect what your current platform misses.

Ultra-sensitive ctDNA monitoring for your clinical trial, your laboratory, your patients. Delivered as a service from our EU lab, or run on your own instruments.

Find your starting point → Speak to our scientific team →

✓ Parts-per-million sensitivity · Open pipeline, raw data access · EU-based

Scientist working with pipettes in the Simsen lab

Where to start

Three audiences. Three places to begin.

Whoever you are, start with the outcome you need. The science is one click deeper, for when you want it.

For clinical trials

Validate MRD endpoints. Move faster.

Design ctDNA endpoints into your European oncology trial, with raw data access and co-publication built in.

Learn more →

For research & labs

See signals others miss.

Send samples, or bring SiMSen-Seq in-house on your own instruments. Low-AF detection in paediatric and early-stage samples.

Learn more →

For clinics

Catch relapse before imaging does.

Personalised ctDNA monitoring for your oncology patients, with European logistics and time-zone-aligned support.

Learn more →

Why Simsen

Ultra-sensitive ctDNA, delivered your way.

Five reasons researchers, pharma teams and clinics across Europe choose to work with us.

Sensitivity

You detect signal at parts-per-million, in samples your current platform calls negative.

Flexibility

You choose: send samples to our lab, or run SiMSen-Seq on your own instruments.

Clinical insight

You see actionable variants and tumour evolution, not just a binary positive or negative.

Transparency

You get full raw data access and an open pipeline. Your bioinformatics team can verify, reanalyse or extend our results with their own tools.

Partnership

You work with a specialist team: co-publication, protocol design and interpretation help.

Evidence

What ultra-sensitivity looks like for the people doing the work.

0.001 % VAF

Variant allele frequency you can detect, in your own samples.

Rostamzadeh et al., 2026 →

9 months

Earlier than imaging picked up relapse, in paediatric neuroblastoma monitoring.

Ek et al., 2024 →

68 %

Of surveillance scans could have been avoided, in ctDNA-monitored metastatic breast cancer.

MOUHANNA ET AL., 2025 →

Methodology

Three ways to monitor ctDNA. They are not interchangeable.

Tumour-informed monitoring splits broadly into three approaches: tracking single nucleotide variants, tracking structural variants, or using fixed tumour-naive panels. Each has consequences for your samples. Most platforms hide this choice. We think it deserves daylight.

Simsen approach

SNV-based

Personalised and ultra-sensitive, surfacing clinically actionable variants alongside tumour markers.

Best when: small biopsies, low tumour burden, you want resistance signal.

SV-based

Personalised, sensitive in tumour types with high structural-variant burden, but no resistance information.

Best when: SV-rich tumours, resistance tracking not required.

Tumour-naive

Fixed panel, no biopsy needed, lower sensitivity at very low allele frequencies.

Best when: no tissue available, sensitivity is secondary.

Read the full methodology framework